NCT04159974View on ClinicalTrials.gov

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

PHASE2UnknownINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Esophageal Adenocarcinoma

Interventions

DRUG

Durvalumab 50 MG/ML

IV Infusion

DRUG

Tremelimumab

IV Infusion, Combination with Durvalumab

Trial Locations (2)

50937

University of Cologne, Cologne

81377

Klinikum der Universität München, München

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

University of Cologne

OTHER